CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 184 enrolled
Drug / intervention
Varenicline +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02460900
NCT02460900Phase 3Completed

Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke

University of Maryland, Baltimore·interventional·Posted Jun 3, 2015·Updated Mar 13, 2025

In Brief

A Phase 3 clinical trial evaluating Varenicline, Positively Smoke Free, and 2 other interventions for Smoking and HIV. Completed, enrolled 184 participants across 1 site.

Detailed Summary

The single greatest health behavior change that could improve cardiovascular morbidity and associated mortality is to assist people living with HIV/AIDS who smoke to quit. The investigators will use a factorial design to evaluate the most promising behavioral and pharmacologic treatments aimed at achieving maximal efficacy for smoking cessation among people living with HIV/AIDS who smoke. Results of this study will provide crucial, real world evidence of the best way for healthcare providers to help smokers living with HIV/AIDS quit smoking.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking, HIV
CountriesUnited States

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 3, 2015
Enrollment StartJul 1, 2016
Primary CompletionApr 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 11.1 years ago

Interventions

Vareniclinedrug

Positively Smoke Freebehavioral

Placebodrug

Standard of Carebehavioral